Abstract
The effects of N2-(N-acetyl-muramyl-l-alanyl-d-isoglutamyl)-N6-stearoyl-l-lysine (MDP-Lys(L18)), a muramyl dipeptide (MDP) analog, on the immune responses in mice were studied. MDP-Lys(L18) augmented the mitogenic responses of splenic lymphocytes to phytohemagglutinin (PHA) and lipopolysaccharide (LPS) at 0.1–10 μg/ml, and antibody formation to sheep red blood cell (SRBC) in normal and immunosuppressed mice, and to dinitrophenyl (DNP)-Ficoll. In addition, MDP-Lys(L18) potentiated polyclonal B cell activation bothin vivo andin vitro. It was also found that MDP-Lys(L18) augmented the cellular immune responses, such as mixed lymphocyte reaction (MLR) and delayed type hypersensitivity (DTH). These effects of MDP-Lys(L18) were more potent than those of MDP. These findings may be attributed to the interleukin 1 (IL-1)-inducing activity of MDP-Lys(L18).
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
F. Ellouz, A. Adam, R. Ciorbaru and E. Lederer,Minimal structural requirement for adjuvant activity of bacterial peptidoglycan derivatives. Biochim. Biophys. Res. Commun.59, 1317–1325 (1974).
S. Kotani, Y. Watanabe, T. Shimono, F. Kinoshita, T. Narita, K. Kato, D. E. S. Stewart-Tull, I. Morisaki, K. Yokogawa and S. Kawata,Immunoadjuvant activities of peptidoglycan subunits from the cell walls of Staphylococcus aureus and Lactobacillus plantarum, Biken J.18, 93–103 (1975).
L. Chedid, F. Audibert, P. Lefrancier, J. Choay and E. Lederer,Modulation of the immune response by a synthetic adjuvant and analogs, Proc. Natl. Acad. Sci. USA73, 2472–2475 (1976).
L. Chedid, M. Parant, F. Parant, P. Lefrancier, J. Choay and E. Lederer,Enhancement of nonspecific immunity to Klebsiella pneumoniae by a synthetic immunoadjuvant (N-acetylmuramyl-l-alanyl-d-isoglutamine) and several analogs. Proc. Natl. Acad. Sci. USA74, 2089–2093 (1977).
K. Matsumoto, H. Ogawa, T. Kusama, O. Nagase, N. Sawaki, M. Inage, S. Kusumoto, T. Shiba and I. Azuma,Stimulation of nonspecific resistance to infection induced by 6-O-acyl muramyl dipeptide analogs in mice, Infect. Immun.32, 748–758 (1981).
K. Matsumoto, Y. Osada, T. Une, T. Otani, H. Ogawa and I. Azuma,Anti-infectious activity of the synthetic muramyl dipeptide analogue MDP-Lys(L18). InImmunostimulants: Now and Tomorrow (Eds. I. Azuma and G. Jollés) pp. 79–97, Japan Sci. Soc. Press/Springer-Verlag, Berlin 1987.
I. Azuma, K. Sugimura, T. Taniyama, M. Yamawaki, Y. Yamamura, S. Kusumoto, S. Okada and T. Shiba,Adjuvant activity of mycobacterial fractions: Adjuvant activity of synthetic N-acetylmuramyl-dipeptide and the related compounds, Infect. Immun.14, 18–27 (1976).
S. Specter, R. Cimprich, H. Friedman and L. Chedid,Stimulation of an enhanced in vitro immune response by a synthetic adjuvant, muramyl dipeptide, J. Immunol.120, 487–491 (1978).
C. Leclerc, D. Juy, E. Bourgeous and L. Chedid,In vitro regulation of humoral and cellular immune responses of mice by a synthetic adjuvant, N-acetyl-muramyl-l-alanyl-d-isoglutamine, muramyldipeptide for MDP, Cell. Immunol.45, 199–206 (1979).
E. Lederer,Synthetic immunostimulants derived from the bacterial cell wall, J. Med. Chem.23, 819–825 (1980).
A. J. Cunningham and A. Szenberg,Further improvements in the plaque technique for detecting single antibody-forming cells, Immunology14, 599–600 (1968).
J. K. Inman,Thymus-independent antigens: The preparation of covalent, hapten-Ficoll conjugates J. Immunol.114, 704–709 (1975).
S. B. Mizel, J. J. Oppenheim and D. L. Rosenstreich,Characterization of lymphocyte activating factor (LAF) produced by the macrophage cell line P388D 1:I. Enhancement of LAF production by activated T lymphocytes, J. Immunol.120, 1497–1503 (1978).
K. Sugimura, M. Uemiya, I. Saiki, I. Azuma and Y. Yamamura,The adjuvant activity of synthetic N-acetylmuramyl-dipeptide: Evidence of initial target cells for the adjuvant activity. Cell. Immunol.43, 137–149 (1979).
D. L. Peavy and C. W. Pierce,Cell-mediated immune response in vitro I. Suppression of the generation of cytotoxic lymphocytes by concanavalin A and concanavalin A-activated spleen cells, J. Exp. Med.140, 356–369 (1974).
L. Shou, S. A. Schwaltz and R. A. Good,Suppressor cell activity after concanavalin A treatment of lymphocytes from normal donors, J. Exp. Med.143, 1100–1110 (1976).
S. Kotani, H. Takada, M. Tsujimoto, T. Ogawa, Y. Mori, T. Koga, H. Iribe, A. Tanaka, S. Nagao, J. R. McGhee, S. M. Michalek, I. Morisaki, C. Nishimura, I. Ikeda, O. Kohashi, H. Ogawa, S. Hamada, S. Kawata, T. Shiba and S. Kusumoto,Lipophilic muramyl peptides and synthetic lipid A analogs as immunomodulators. InProgress in Immunology V (Eds. Y. Yamamura and T. Tada) pp. 1359–1377, Academic Press, Tokyo 1983.
M. J. Staruch and D. D. Wood,Genetic influences on the adjuvanticity of muramyl dipeptide in vivo, J. Immunol.128, 155–160 (1982).
J. J. Oppenheim, E. J. Kovacs, K. Matsushima and S. K. Durum,There is more than one interleukin 1, Immunology Today7, 45–56 (1986).
M. Guenounou, F. Vacheron and C. Nouciel,Interleukin 1, a mediator of immunoadjuvant peptidoglycans, Comp. Immunol. Microbiol. Infect. Dis.8, 273–284 (1985).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Akasaki, M., Takashi, T., Kita, Y. et al. Augmentation of immune responses by a muramyl dipeptide analog, MDP-Lys(L18). Agents and Actions 22, 144–150 (1987). https://doi.org/10.1007/BF01968830
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01968830